News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
Can DOGE reclaim $0.50? Altseason signals and Musk noise collide at $0.195
Crypto.News·2026/05/12 14:51
Circle stock rallies 16% on Q1 beat, yet momentum looks extended
CryptoNewsNet·2026/05/12 14:49
Poland lawmakers debate crypto bills as PiS party submits separate ban proposal
The Block·2026/05/12 14:48
Euro falls as hot US inflation data boosts Fed higher-for-longer expectations
FXStreet·2026/05/12 14:45
Solana price retreats from $100 after rejection, will upcoming SMA crossover trigger rebound?
Crypto.News·2026/05/12 14:45
BlackRock files second tokenized fund with SEC, doubling down on Securitize
Crypto.News·2026/05/12 14:45
Arkham Drops TON: Blockchain Analytics Leader Pulls Support as Toncoin Hits Yearly High
BlockchainReporter·2026/05/12 14:42
Can Bitcoin break $100K as the CLARITY Act heads to committee?
Crypto.News·2026/05/12 14:42
Silver price forecast: CPI data could trigger next big breakout move
CryptoNewsNet·2026/05/12 14:39
Flash
20:12
Oklo reports Q1 loss of $0.19 per share, in line with analyst expectationsQ1 research and development operating expenses were $27 million, compared to analysts' expectations of $16.1 million.
20:09
Thanks to the strong performance of its patient payment affordability solutions, Paysign Inc achieved a 51% revenue growth in the first quarter of 2026, while profit margins also saw significant improvement.This performance highlights the company's dual achievements in market penetration and operational efficiency within the medical payment sector.
20:09
TriSalus Life Sciences Inc. (TLSI) released its financial and operational results for the first quarter of 2026. During the reporting period, the company made significant progress in both commercial promotion and clinical development, paving the way for its future long-term growth.The earnings report shows that the company’s core products are experiencing strong commercial momentum, with market penetration continuing to increase. At the same time, several key clinical studies are progressing as planned and have produced positive interim data, further validating the potential and value of its innovative therapies. The company’s management stated that the first quarter’s performance was in line with expectations, and the simultaneous commercial and clinical progress directly reflects the execution of the long-term strategy. They believe that these solid foundational efforts will strongly drive the company’s value to continue to be released over the next few quarters.
Trending news
MoreSOLV (SOLV) 24-hour volatility reaches 55.2%: trading volume surges over $50 million driving rebound
Thanks to the strong performance of its patient payment affordability solutions, Paysign Inc achieved a 51% revenue growth in the first quarter of 2026, while profit margins also saw significant improvement.